Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.

Valaasani KR, Sun Q, Hu G, Li J, Du F, Guo Y, Carlson EA, Gan X, Yan SS.

Curr Alzheimer Res. 2014 Feb;11(2):128-36.

2.

Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.

Lim YA, Grimm A, Giese M, Mensah-Nyagan AG, Villafranca JE, Ittner LM, Eckert A, Götz J.

PLoS One. 2011;6(12):e28887. doi: 10.1371/journal.pone.0028887. Epub 2011 Dec 12.

3.

Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.

Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS.

J Neurosci. 2011 Feb 9;31(6):2313-20. doi: 10.1523/JNEUROSCI.4717-10.2011.

4.

Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.

Zakaria A, Hamdi N, Abdel-Kader RM.

Mol Neurobiol. 2016 Mar;53(2):1220-8. doi: 10.1007/s12035-014-9088-8. Epub 2015 Jan 20.

PMID:
25601181
5.

ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction.

Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, Yan SS.

FASEB J. 2005 Apr;19(6):597-8. Epub 2005 Jan 21.

PMID:
15665036
6.

In silico-designed novel non-peptidic ABAD LD hot spot mimetics reverse Aβ-induced mitochondrial impairments in vitro.

Viswanath ANI, Kim T, Jung SY, Lim SM, Pae AN.

Chem Biol Drug Des. 2017 Dec;90(6):1041-1055. doi: 10.1111/cbdd.13065. Epub 2017 Jul 27.

PMID:
28660722
7.

ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease.

Marques AT, Fernandes PA, Ramos MJ.

Mini Rev Med Chem. 2009 Jul;9(8):1002-8.

PMID:
19601895
8.

Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.

Hroch L, Benek O, Guest P, Aitken L, Soukup O, Janockova J, Musil K, Dohnal V, Dolezal R, Kuca K, Smith TK, Gunn-Moore F, Musilek K.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3675-8. doi: 10.1016/j.bmcl.2016.05.087. Epub 2016 May 30.

PMID:
27287370
9.

[Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].

Benek O, Musílek K, Kuca K.

Ceska Slov Farm. 2012 Aug;61(4):144-9. Review. Czech.

PMID:
23251955
10.

Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.

Hroch L, Guest P, Benek O, Soukup O, Janockova J, Dolezal R, Kuca K, Aitken L, Smith TK, Gunn-Moore F, Zala D, Ramsay RR, Musilek K.

Bioorg Med Chem. 2017 Feb 1;25(3):1143-1152. doi: 10.1016/j.bmc.2016.12.029. Epub 2016 Dec 27.

PMID:
28082069
11.

ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.

Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H.

Science. 2004 Apr 16;304(5669):448-52.

12.

Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease.

Valasani KR, Hu G, Chaney MO, Yan SS.

Chem Biol Drug Des. 2013 Feb;81(2):238-49. doi: 10.1111/cbdd.12068. Epub 2012 Nov 14.

13.

Mitochondrial β-amyloid in Alzheimer's disease.

Borger E, Aitken L, Muirhead KE, Allen ZE, Ainge JA, Conway SJ, Gunn-Moore FJ.

Biochem Soc Trans. 2011 Aug;39(4):868-73. doi: 10.1042/BST0390868.

PMID:
21787315
14.

Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD).

Powell AJ, Read JA, Banfield MJ, Gunn-Moore F, Yan SD, Lustbader J, Stern AR, Stern DM, Brady RL.

J Mol Biol. 2000 Oct 20;303(2):311-27.

PMID:
11023795
15.

Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?

Borger E, Aitken L, Du H, Zhang W, Gunn-Moore FJ, Yan SS.

Curr Alzheimer Res. 2013 Jan;10(1):21-9. Review.

16.

Identification of small-molecule inhibitors of the Abeta-ABAD interaction.

Xie Y, Deng S, Chen Z, Yan S, Landry DW.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4657-60. Epub 2006 Jun 14.

PMID:
16781151
17.

Curcumin-mediated neuroprotection against amyloid-β-induced mitochondrial dysfunction involves the inhibition of GSK-3β.

Huang HC, Xu K, Jiang ZF.

J Alzheimers Dis. 2012;32(4):981-96. doi: 10.3233/JAD-2012-120688.

PMID:
22886017
18.
19.

Cytoprotective role of mitochondrial amyloid beta peptide-binding alcohol dehydrogenase against a cytotoxic aldehyde.

Murakami Y, Ohsawa I, Kasahara T, Ohta S.

Neurobiol Aging. 2009 Feb;30(2):325-9. Epub 2007 Aug 20.

PMID:
17707551
20.

Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.

Kissinger CR, Rejto PA, Pelletier LA, Thomson JA, Showalter RE, Abreo MA, Agree CS, Margosiak S, Meng JJ, Aust RM, Vanderpool D, Li B, Tempczyk-Russell A, Villafranca JE.

J Mol Biol. 2004 Sep 17;342(3):943-52.

PMID:
15342248

Supplemental Content

Support Center